Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at Zacks Research lifted their Q1 2024 earnings per share estimates for Allogene Therapeutics in a report issued on Tuesday, February 6th. Zacks Research analyst S. Ganoria now expects that the company will earn ($0.48) per share for the quarter, up from their prior forecast […]
Related Keywords
Deborahm Messemer , , Allogene Therapeutics Company Profile , Zacks Research , Great West Life Assurance Co , Manufacturers Life Insurance Company , Citigroup , Ieq Capital , Nasdaq , Ensign Peak Advisors Inc , Allogene Therapeutics Inc , Allogene Therapeutics , Free Report , Allogene Therapeutic , West Life Assurance , Peak Advisors Inc , Director Deborah , Get Free Report , Allogene Therapeutics Daily , Nasdaq Allo , Allo , Medical , Earnings Estimates ,
comparemela.com © 2020. All Rights Reserved.